Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $96.00 Price Target at Stifel Nicolaus

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective lowered by Stifel Nicolaus from $104.00 to $96.00 in a research report released on Friday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. Chardan Capital restated a “buy” rating and issued a $115.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. B. Riley Financial upped their price target on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. UBS Group initiated coverage on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. They set a “buy” rating and a $109.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $98.93.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $47.78 on Friday. Arrowhead Pharmaceuticals has a 52-week low of $37.06 and a 52-week high of $95.49. The firm has a market capitalization of $6.73 billion, a PE ratio of -9.35 and a beta of 1.34. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. The business’s 50-day simple moving average is $63.32 and its 200 day simple moving average is $71.00.

Insider Activity

In other news, Director Adeoye Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Perry sold 11,600 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $1,208,838,000. Siren L.L.C. boosted its position in shares of Arrowhead Pharmaceuticals by 7.7% in the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after purchasing an additional 115,000 shares in the last quarter. Jupiter Topco LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth about $99,623,000. Janus Henderson Group PLC increased its position in shares of Arrowhead Pharmaceuticals by 12.2% during the first quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock valued at $90,119,000 after acquiring an additional 156,544 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Arrowhead Pharmaceuticals in the 2nd quarter valued at approximately $70,061,000. Institutional investors own 62.61% of the company’s stock.

Key Arrowhead Pharmaceuticals News

Investors following ARWR have been watching these news items:

• Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and $100 price target, signaling continued analyst confidence in Arrowhead’s potential. Royal Bank of Canada rating
• Neutral Sentiment: Stifel Nicolaus kept its “buy” rating but lowered its price target to $96 from $104, reflecting a more cautious valuation while retaining a bullish view. Stifel Nicolaus rating
• Negative Sentiment: Arrowhead reported a full-year fiscal 2026 loss of $5.11 per share. An earnings analysis also highlights the challenge of making costly R&D pay off as market sentiment toward RNA interference (RNAi) turns more skeptical. Full-year earnings results Earnings analysis

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.